研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

癌症免疫逃逸和免疫治疗中的CD155及其受体。

CD155 and its receptors in cancer immune escape and immunotherapy.

发表日期:2023 Sep 01
作者: Ruijia Zhou, Shiyin Chen, Qiwen Wu, Lingyun Liu, Yian Wang, Yongzhen Mo, Zhaoyang Zeng, Xuyu Zu, Wei Xiong, Fuyan Wang
来源: CANCER LETTERS

摘要:

近年来,癌症免疫治疗取得了多项突破, 免疫检查点抑制剂成为最有前途的治疗策略。然而,现有药物并不总是有效。作为新兴的免疫检查点分子,CD155已经成为免疫治疗的重要目标。本综述描述了CD155的结构和功能,以及其受体TIGIT、CD96和CD226,并总结了CD155通过DNA损伤应答通路和Ras-Raf-MEK-ERK信号通路可以上调肿瘤细胞中的表达。本综述还阐述了CD155与其受体TIGIT、CD96和CD226结合后的免疫逃逸机制,并总结了关于CD155及其受体的免疫治疗研究的当前进展。此外,本文还讨论了检查点免疫治疗的未来方向。版权所有 © 2023. Elsevier B.V. 发布。
In recent years, there have been multiple breakthroughs in cancer immunotherapy, with immune checkpoint inhibitors becoming the most promising treatment strategy. However, available drugs are not always effective. As an emerging immune checkpoint molecule, CD155 has become an important target for immunotherapy. This review describes the structure and function of CD155, its receptors TIGIT, CD96, and CD226, and summarizes that CD155 expressed by tumor cells can upregulate its expression through the DNA damage response pathway and Ras-Raf-MEK-ERK signaling pathway. This review also elaborates the mechanism of immune escape after binding CD155 to its receptors TIGIT, CD96, and CD226, and summarizes the current progress of immunotherapy research regarding CD155 and its receptors. Besides, it also discusses the future direction of checkpoint immunotherapy.Copyright © 2023. Published by Elsevier B.V.